The contract, as well as the funding of a study of IV TPOXX, “highlight the growing importance of a broad-based response to the substantial risks posed by the orthopox family of viruses, including smallpox and monkeypox,” Phil Gomez, PhD, the CEO of SIGA, said in the statement.
“We will continue to coordinate with the U.S. government toward future procurements of oral TPOXX and IV TPOXX,” he said.
The oral and IV versions of TPOXX are approved by the FDA for the treatment of smallpox, though they aren’t yet approved for monkeypox, according to Reuters. But the CDC has provided guidance for use under “expanded access” as an experimental drug.
The U.S. leads the world in monkeypox cases, with nearly 9,500, followed by Spain with more than 5,000, Germany with nearly 3,000, and the U.K. with more than 2,900. France and Brazil have also reported more than 2,000 cases, with the rest of the countries reporting fewer than 1,000 cases.
In the U.S., New York leads the country with more than 2,000 cases, according to the latest CDC data. California has reported about 1,300 cases, followed by Florida with 976 cases, and Georgia, Texas, and Illinois with more than 700 cases. The rest of the states have reported fewer than 300 cases, with only Wyoming reporting no cases so far.